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Background: Patients with pathological stage IA adenocarcinoma 
(AC) have a variable prognosis, even if treated in the same way. The 
postoperative treatment of pathological stage IA patients is also 
controversial.
Methods: We identified 176 patients with pathological stage IA AC 
who had undergone a lobectomy and mediastinal lymph node dis-
section at the Shanghai Chest Hospital, Shanghai, China, between 
2000 and 2006. No patient had preoperative treatment. The histo-
logic subtypes of all patients were classified according to the 2011 
International Association for the Study of Lung Cancer (IASLC)/
American Thoracic Society (ATS)/European Respiratory Society 
(ERS) international multidisciplinary lung AC classification. Patients’ 
5-year overall survival (OS) and 5-year disease-free survival (DFS) 
were calculated using Kaplan–Meier and Cox regression analyses.
Results: One hundred seventy-six patients with pathological stage IA 
AC had an 86.6% 5-year OS and 74.6% 5-year DFS. The 10 patients 
with micropapillary predominant subtype had the lowest 5-year DFS 
(40.0%).The 12 patients with solid predominant with mucin pro-
duction subtype had the lowest 5-year OS (66.7%). Univariate and 
multivariate analysis showed that sex and prognositic groups of the 
IASLC/ATS/ERS histologic classification were significantly associ-
ated with 5-year DFS of pathological stage IA AC.
Conclusion: Our study revealed that sex was an independent prog-
nostic factor of pathological stage IA AC. The IASLC/ATS/ERS 
classification of lung AC identifies histologic categories with prog-
nostic differences that could be helpful in clinical therapy.
Key Words: Lung, Adenocarcinoma, Classification, International 
Association for the Study of Lung Cancer/American Thoracic 
Society/European Respiratory Society, Pathologic tumor node 
metastasis Ia.
(J Thorac Oncol. 2013;8: 1196-1202)
Lung cancer continues to be the leading cause of can-cer deaths in both men and women in the world.1 
Adenocarcinoma (AC) is the most common histologic type 
of primary lung cancer.2 The correct diagnosis of lung cancer 
depends on the pathologic examination of cytologic or his-
tologic specimens. It is a major focus of research to improve 
patient survival. The international multidisciplinary lung AC 
classification proposed by International Association for the 
Study of Lung Cancer (IASLC)/American Thoracic Society 
(ATS)/Europen Respiratory Society (ERS)3 provided con-
sistent terms and diagnostic criteria for AC subtypes. New 
concepts were introduced for surgical specimens, such as 
adenocarcinoma in situ (AIS) and minimally invasive ade-
nocarcinoma (MIA). In the new classification, bronchio-
loalveolar carcinoma (BAC) was replaced by AIS for small 
solitary ACs with pure lepidic growth. MIA was described 
as small (≤3 cm) solitary ACs with predominant lepidic 
growth and invasion of 5 mm or lesser. Another important 
change included elimination of the mixed subtype AC. 
Invasive ACs were classified by predominant pattern after 
using comprehensive histologic subtyping with lepidic (for-
merly most mixed subtype tumors with nonmucinous BAC), 
acinar, papillary, solid, and micropapillary patterns. Each 
histologic subtype present in a tumor was estimated in 5% 
increments. According to the 2011 National Comprehensive 
Cancer Network Clinical Practice Guidelines in Oncology 
for non–small-cell lung cancer, stage pathologic tumor node 
metastasis (pTNM) Ia patients with complete resection are 
treated with observation. Adjuvant chemo- or radiotherapy 
was not recommended. The survival of pathological stage 
IA patients is theoretically much better than that of patients 
with other stages if they accept surgical therapy. However, 
previous reports show a relatively wide range of 5-year 
survival in pathological stage IA patients, from 77.0% to 
94.4%.4–6 Patients with stage IA AC undergoing the same 
treatments also had variable outcomes (recurrence, metas-
tasis, and death). Important factors in predicting prognosis, 
such as histologic subtype, tumor size, and type of surgi-
cal therapy, may also predict survival. A consensus for post-
operative treatment in pathological stage IA patients has 
not been reached. Yoshizawa et al.7 validated the new AC 
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classification with a North American data set that comprised 
514 patients with stage I lung AC. Russell et al.8 also identi-
fied 210 patients with lung AC to confirm the utility of the 
new classification. Both reports demonstrated a correlation 
between AC subtype and patient survival, supporting the 
valuable prognostic role of the new classification. The prog-
nostic impact of the new histologic classification still needs 
further validation. Against this background, we investigated 
the clinical utility of the new classification to predict patient 
outcome at the Shanghai Chest Hospital, Shanghai, China.
PATIENTS AND METHODS
Patient Selection
The records of 176 patients with pathological stage 
IA AC, who had undergone a lobectomy with mediastinal 
lymph node dissection at the Shanghai Chest Hospital, from 
2000 to 2006, were reviewed. No patient received preopera-
tive treatment. Patients were excluded if they had adjuvant 
chemotherapy or radiotherapy. All patients were regularly 
followed up after surgery. Patients were examined on an out-
patient basis at 3-month intervals for the first 2 years and 
at 6-month intervals thereafter. The follow-up evaluation 
included physical examination, blood examination, com-
puted tomography scan of the chest and abdomen, brain 
magnetic resonance imaging, and bone scintigraphy. Distant 
metastasis at N3 lymph node was comfirmed by fine-needle 
aspiration and cytopathological diagnosis when clinically 
feasible. The median follow-up time for the entire group was 
73 months (range, 10–147 months).
Histologic Evaluation
All specimens were categorized according to the IASLC/
ATS/ERS classification of lung AC. Tumors were classified as 
AIS (Fig. 1), MIA (Fig. 2), or invasive AC. Invasive AC was 
divided into lepidic predominant (Fig. 3), acinar predomi-
nant (Fig. 4), papillary predominant (Fig. 5), micropapillary 
predominant (Fig. 6), solid predominant (Fig. 7), invasive 
mucinous AC (Fig. 8), colloid AC subtypes (Fig.9), and fetal 
AC (Fig.10). The predominant pattern was defined as the pat-
tern with the largest percentage. Two pathologists, blinded to 
patients’ outcome, independently reviewed all hematoxylin 
and eosin–stained slides. If differences emerged on the same 
slide, the reviewers would reach a consensus during discus-
sion and multihead microscopy examination.
Visceral pleural invasion was assessed in all patients, 
using guidelines of the 7th edition of the TNM classification 
for lung cancer.9,10 All 176 patients were confirmed to have no 
visceral pleural involvement using elastic staining.
Statistical Analysis
Overall survival (OS) or disease-free survival (DFS) 
in each separate histologic subtype was assessed using a 
Kaplan–Meier analysis. Age, sex, location, tumor gross size, 
tumor invasive size, and prognostic groups of the IASLC/ATS/
ERS histologic classification were included in the univariate 
analysis. Multivariate analysis was performed for variables 
that were identified to be significant in the univariate analysis. 
Statistical analysis was conducted using SPSS version 17.0 
(SPSS Inc., Chicago, IL).
RESULTS
Clinicopathological Characteristics
Of the patients, 50.6% (89 of 176) were men and 49.4% 
(87 of 176) were women. The median age at presentation 
was 58 years (range, 30–79 years); 39.2% of patients had a 
right upper lobe tumor and 26.7% a left upper lobe tumor. 
The median tumor size was 1.9 cm (range, 0.5–3.0 cm). The 
most frequent histologic subtype was papillary predominant 
FIGURE 1.  Adenocarcinoma in situ, this tumor shows lepidic 
growth consisting of alveolar wall thickening by atypical 
pneumocyte proliferation. No invasive growth area is seen 
(Hematoxylin and Eosin,×100). 
FIGURE 2.  Minimally invasive adenocarcinoma, this tumor 
consists of mostly lepidic growth but there is an invasive area 
not more than 5mm in diameter, with a papillary growth pat-
tern (Hematoxylin and Eosin,×100).
1198 Copyright © 2013 by the International Association for the Study of Lung Cancer
Zhang et al. Journal of Thoracic Oncology ®  •  Volume 8, Number 9, September 2013
(40.9%, 72 of 176), followed by acinar predominant, MIA, 
lepidic predominant, solid predominant with mucin produc-
tion, and micropapillary subtypes. These accounted for 22.7% 
(40 of 176), 9.1% (16 of 176), 7.9% (14 of 176), 6.8% (12 
of 176), and 5.7% (10 of 176), respectively, of all patients. 
All AIS and MIA tumors were of the nonmucinous type 
(Table 1).
Survival Analysis
Five-year DFS was 74.6% (Table 2). The 10 patients 
with micropapillary predominant subtype had the lowest 
5-year DFS (40.0%), followed by those with papillary pre-
dominant subtype (65.6%), solid predominant with mucin 
production (66.7%), and variants of invasive AC (66.7%). 
Five-year OS was 86.6%. The 12 patients with solid pre-
dominant with mucin production subtype had the lowest 
5-year OS (66.7%), followed by patients with micropapil-
lary predominant (80.0%), variants of invasive AC (83.3%), 
and acinar predominant (85.0%) (Table 2). On the basis of 
5-year DFS, patients with different histologic subtypes were 
divided into three groups. The first group, AIS and MIA, had 
a 100% 5-year DFS. The second group, lepidic predomi-
nant and acinar predominant subtypes, had an 85.2% 5-year 
DFS. The third group, papillary predominant, micropapil-
lary predominant, solid predominant with mucin produc-
tion, and variants of invasive AC, had a 62.8% 5-year DFS. 
There was a significant difference in 5-year DFS among the 
three groups (p < 0.001) (Fig. 11). Patients with variants of 
FIGURE 3.  Lepidic predominant, this tumor consists of 
mostly lepidic growth but there is an invasive area more 
than 5 mm in diameter, with an acinar growth pattern 
(Hematoxylin and Eosin,×40).
FIGURE 4.  Acinar predominant, this tumor is composed of 
round-to-oval–shaped glands consisting of atypical epithelial 
cells showing nuclear hyperchromasia and prominent nucleoli 
(Hematoxylin and Eosin,×200).
FIGURE 5.  Papillary predominant, this tumor shows a papil-
lary pattern with cuboidal cells growing along the surface of 
fibrovascular cores (Hematoxylin and Eosin,×200).
FIGURE 6.  Micropapillary predominant, this tumor shows 
glandular cells growing in small papillary tufts lacking fibro-
vascular cores (Hematoxylin and Eosin,×200).
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invasive AC had a similar 5-year DFS to those with solid 
predominant with mucin production. In our series, only one 
patient had colloid AC. Surgical resection was performed 
in April 2000, followed by rapid progression and death in 
February 2001. Two patients with fetal subtype were alive 
without recurrence or metastases. One tumor was high grade 
and the other low grade.
There was significant difference with respect to DFS 
among different histologic subtypes (p < 0.001). Women had 
a significantly greater 5-year DFS than men (81.2% versus 
68.1%; p = 0.011) (Fig. 12). Neither age (p = 0.662) nor tumor 
location (p = 0.363) affected 5-year DFS. There was no cor-
relation of DFS with either tumor gross size (p = 0.185) or 
tumor invasive size (p = 0.463).
Cox Regression
Univariate analysis and multivariate analysis in the Cox 
regression model both showed that sex (hazard ratio = 2.056; 
95% confidence interval: 1.124–3.761; p = 0.019) and prog-
nostic groups of the IASLC/ATS/ERS histologic classification 
(hazard ratio = 4.446; 95% confidence interval: 2.076–9.525; 
p < 0.001) were significantly associated with 5-year DFS 
(Table 3).
DISCUSSION
Patients with stage IA AC have had a variable 5-year 
survival, ranging from 77.0% to 94.4%.4–6 Our patients had 
FIGURE 7.  Solid predominant with mucin production, this 
tumor is composed of solid sheets of tumor cells with intra-
cellular mucin production (Hematoxylin and Eosin,×200).
FIGURE 8.  Invasive mucinous adenocarcinoma, this tumor 
shows tall columnar mucinous cells line along the alveolar 
walls with penetration of fibrous stroma (Hematoxylin and 
Eosin, ×200).
FIGURE 9.  Colloid adenocarcinoma, this tumor consists 
of pools of mucin filling air spaces with well-differentiated 
malignant glands growing along the edges of the surround-
ing connective tissue (Hematoxylin and Eosin,×200).
FIGURE 10.  Fetal adenocarcinoma, this tumor shows 
adenoid structure similar to endometrial glands, lined by 
pseudo-stratified epithelial cells containing glycogen vacuoles 
(Hematoxylin and Eosin,×200).
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an 86.6% 5-year OS, and 74.6% 5-year DFS. The prognosis 
for patients with surgically resected stage IA AC could be 
improved. Multiple factors might influence their long-term 
survival and frequency of recurrence. Tsuneyo et al.11 pointed 
out that lymph node metastases not observed during surgery 
could be identified during pathological examination. Patients 
without segmental lymph node sampling may be understaged, 
leading to incorrect treatment. The poor prognosis associ-
ated with stage IA AC implies that the current T descriptor 
(tumor size) does not completely reflect the biological behav-
ior of the tumors. In our patients, neither tumor gross size 
nor invasive size had correlation with 5-year DFS. Yoshizawa 
et al.7 pointed out that both tumor gross size (p = 0.04) and 
invasive size adjusted by the percentage of lepidic growth 
(p = 0.026) were poor prognostic factors in stage I AC. There 
is still, however, other conflicting evidence to support the 
impact of tumor size as a prognostic factor in stage Ia non–
small-cell lung cancer.12–16
The current pTNM staging system does not consider 
histopathology or tumor differentiation.17 Sakao et al.5 
reported that tumors with a BAC component exhibited less 
invasion and aggressive biological behavior, and that it was 
the size of the non-BAC component that was prognostic. In 
2011, the new IASLC/ATS/ERS classification of lung AC 
was proposed to identify histologic categories with prognos-
tic differences. Yoshizawa et al.7 reported the IASLC/ATS/
ERS histologic classification was predictive of prognosis in 
stage I AC (p = 0.038). Their data set revealed that AIS and 
MIA had a 100.0% 5-year DFS. Nonmucinous lepidic pre-
dominant, papillary predominant, and acinar predominant 
subtypes had 90.0%, 83.0%, and 84.0% 5-year DFS, respec-
tively. Invasive mucinous AC, colloid adenocarcinoma, 
TABLE 1.  Clinicopathologic Characteristics of 176 
Pathological Stage IA Adenocarcinoma Patients
Clinicopathologic 
Characteristics Total Men Women
Sex 176 89 87
Age, yr
  Range 30–79 30–79 34–76
  Median 58 59 58
Tumor gross size (cm)
  Range 0.5–3
  Median 1.9
  ≤2 115 69 46
  >2 61 20 41
Tumor invasive sizea (cm)
  Median 1.8
  ≤1.8 106 60 46
  >1.8 70 29 41
Tumor location
  RUL 69 37 32
  RML 15 8 7
  RLL 23 10 13
  LUL 47 26 21
  LLL 22 8 14
Predominant subtype
  AIS 6 4 2
  MIA 16 6 10
  Lepidic 14 10 4
  Acinar 40 16 24
  Papillary 72 32 40
  Solid 12 10 2
  Micropapillary 10 6 4
  Variantsb 6 5 1
aAdjusted for percentage of lepidic growth.
bVariants of invasive adenocarcinoma includes invasive mucinous adenocarcinoma, 
colloid and fetal subtypes.
RUL, right upper lobe; RML, right middle lobe; RLL, right lower lobe; LUL, left 
upper lobe; LLL, left lower lobe, AIS, adenocarcinoma in situ; MIA, minimally invasive 
adenocarcinoma.
TABLE 2.  Five-Year DFS and 5-Year OS in 176 Patients with 
Adenocarcinoma
Total Recurrence
SD
5-Year 
DFS Death
5-year 
OS
SDN n (%) n (%)
AIS 6 0 — 100 0 100 —
MIA 16 0 — 100 0 100 —
Lepidic 14 2 0.094 85.7 0 100 —
Acinar 40 6 0.056 85 6 85 0.056
Papillary 72 26 0.057 65.6 14 85.5 0.042
Solid 12 4 0.136 66.7 4 66.7 0.136
Micropapillary 10 6 0.155 40 2 80 0.126
Variantsa 6 3 0.192 66.7 1 83.3 0.152
aVariants of invasive adenocarcinoma include invasive mucinous adenocarcinoma, 
colloid and fetal subtypes.
DFS; disease-free survival; AIS, adenocarcinoma in situ; MIA, minimally invasive 
adenocarcinoma; SD, standard deviation; OS, overall survival.
FIGURE 11.  Five-year disease-free survival in the three 
groups: AIS and MIA, lepidic and acinar predominant, papil-
lary, micropapillary, and solid predominant (p < 0.001). 
AIS, adenocarcinoma in situ; MIA, minimally invasive 
adenocarcinoma.
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solid predominant with mucin production, and micropap-
illary predominant subtypes had 75.0%, 71.0%, 70.0%, 
and 67.0% 5-year DFS, respectively. Our findings were 
similar to those of Yoshizawa et al.,7 with AIS and MIA 
being associated with good prognosis, and solid predomi-
nant with mucin production and micropapillary predomi-
nant subtypes associated with poor prognosis. We found the 
5-year DFS in papillary predominant subtype (65.6%) to be 
significantly lower than that reported (83%) by Yoshizawa 
et al.7. This suggested the papillary predominant and solid 
predominant with mucin production subtypes have poor 
prognosis.18 We found that the micropapillary predominant 
subtype was apt to recur or metastasize early, similar to 
literature reports.8,19–21 Patients with this diagnosis require 
further oncologic evaluation and clinical attention. Owing 
to their good prognosis, patients with AIS or MIA may 
be treated with a limited surgical resection (wedge resec-
tion or segmental resection). Whether a limited resection 
provides similar or better result as lobectomy is still ques-
tioned.22 More study is needed to validate this. More atten-
tion should be directed on progression after surgery for 
patients with micropapillary predominant subtype, solid 
predominant with mucin production, and variants of inva-
sive AC subtypes. The relatively poor prognosis (recurrence 
or metastasis) of the lepidic predominant adenocarcinoma 
predominant subtype in our study was likely caused by the 
invasive component such as papillary component.
Sakurai et al.23 and Tsuboi et al.24 reported women with 
AC had a better prognosis than men for pathologic stage I 
disease. In our study, male patients had an obviously poorer 
prognosis than their female counterparts both in univariate 
and multivariate analyses.
In summary, our study revealed that in pathological 
stage IA AC patients, neither tumor gross size nor invasive 
size was related to prognosis. Sex was an independent prog-
nostic factor of pathological stage IA AC. The IASLC/ATS/
ERS classification of lung AC identifies histologic categories 
with prognostic differences that could be helpful in clinical 
therapy. Patients with poor prognostic histologic components, 
such as micropapillary or solid predominant with mucin 
FIGURE 12.  There was a significant difference in 5-year 
disease-free survival between men and women (p = 0.011).
TABLE 3.  Univariate Analysis and Multivariate Analysis with 5-year DFS
Characteristic No. of Patients
5-yr DFS  
Probability (%)
Univariate p Value by 
Log-Rank Test
Multivariate Analysis
HR 95% CI p
Overall 176 74.6 … … … …
Age, yr
  ≤58 88 73.4 0.662 Not included in multivariable model
  >58 88 75.9 …
Sex
  Female 87 81.2 0.011 1 … …
  Male 89 68.1 … 2.050 1.121–3.750 0.020
Location
  Right 107 77.1 0.363 Not included in multivariable model
  Left 69 70.8 …
Tumor gross size
  ≤2 cm (T1a) 115 70.0 0.185 Not included in multivariable model
  >2 cm (T1b) 61 81.4 …
Tumor invasive size
  ≤1.8 cm 106 75.4 0.463 Not included in multivariable model
  >1.8 cm 70 73.3 …
Prognositic groups of  
the new classificationd 176 … <0.001 3.866 1.942–7.698 <0.001
The HR value means the relative risk when the histologic differentiation rises up a level.
dAs a grading indicator, prognostic groups of the new classification are taken as quantitative data in patients’ survival analysis.
CI, confidence interval; DFS, disease-free survival; HR, hazard ratio.
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production, should be monitored more closely for disease 
progression.
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